Consensus Conference on the DGVS on Gastroesophageal reflux. Subject group IV: Erosive reflux disease (ERD);Gastroösophageale Refluxkrankheit - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankhelten: Themenkomplex IV: Erosive refluxkrankheit (ERD)

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 2, 2005, Pages 179-182

  Madisch, A ^a   Hotz, J ^a   Longdong, W ^a   Arnold, R ^a   Gugler, R ^a   Hermans, M L ^a   Layer, P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTACID AGENT; DOMPERIDONE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; SUCRALFATE; PROTON PUMP;

COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG DOSE REGIMEN; ENDOSCOPY; ERADICATION THERAPY; EROSIVE REFLUX DISEASE; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; MONOTHERAPY; ON DEMAND THERAPY; STEP DOWN THERAPY; SYMPTOMATOLOGY; CONSENSUS DEVELOPMENT; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; ESOPHAGOSCOPY; FOLLOW UP; REFLUX ESOPHAGITIS; TREATMENT OUTCOME;

ANTACIDS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FOLLOW-UP STUDIES; HUMANS; PROTON PUMPS; TREATMENT OUTCOME;

EID: 14744305270     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-857874     Document Type: Conference Paper

References (45)

1. Dent J, Brun J, Frederick A et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44: Suppl 2
2. Carlsson R, Dent J, Watts R et al. Gastro-oesophageal reflux disease in primary care: an international study of different tretament strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119-124
3. Revicki DA, Crawley JA, Zodet MW et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 1621-1630
4. Bell NJ, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51 (Suppl 1): 59-67
5. Chiba N, de Gara CJ, Wilkinson JM et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810
6. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1729-1736
7. Wolfe MM, Sachs G. Acid suppression; Optimizing therapy for gastroduodenal ulcer healing, gastroesohageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118: S9-S31
8. Hatlebakk JG, Berstad A. Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scand J Gastroenterol 1996; 31: 954-958
9. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 226: 983-988
10. Fennerty BM, Castell D, Fendrick MA et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Arch Intern Me 1996; 156: 477-484
11. Jones R, Bytzer P. Review article: acid suppression in the management of gastro-oesophageal reflux disease - an appraisal of treatment options in primary care. Aliment Pharmacol Ther 2001; 15: 765-772
12. Isolauri J, Luostarinen M, Isolauri E et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41
13. Singh P, Adamopoulos A, Taylor RH et al. Oesophageal motor function before and after healing of oesophagitis. Gut 1992; 33: 1590-1596
14. Eggleston A, Wigerinck A, Hujjghebaert S et al. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998; 42: 13-16
15. Inadomi JM, Jamal R, Murata GH et al. Step-down management of gastroesophaeal reflux disease. Gastroenterology 2001; 121: 1095-1100
16. Koop H, Kuly S, Flug M et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol 1996; 8: 915-918
17. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-1339
18. Hendel J, Hendel L, Hage E et al. Monitoring of omeprazole treatment in gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 1996; 8: 417-420
19. Bytzer P. On-demand therapy for gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001; 13 (Suppl 1): S19-S22
20. Lind T, Havelund T, Lundell L et al. On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-914
21. Klinkenberg-Knoll EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 661-669
22. Maton PN, Orlando R, Joelsson B. Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease - a prospective controlled trial. Aliment Pharmacol Ther 1999; 13: 819-826
23. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-988
24. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-935
25. Tytgat GNJ. Long-term therapy for reflux esophagitis. N Engl J Med 1995; 333: 1148-1150
26. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-1110
27. Holloway RH, Dent J, Narielvala F et al. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 649-654
28. Carlsson R, Galmiche JP, Dent J et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473-482
29. Jaspersen D, Diehl KL, Schoeppner H et al. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998; 12: 49-52
30. Johnson DA, Benjamin SB, Vakil NB et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol Hepatol 2001; 96: 27-34
31. Dent J, Yeomans ND, Mackinnon M et al. Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590-598
32. Hallerbäck B, Unge P, Carling L et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994; 107: 1305-1311
33. Laine L, Ahnen D, McClain C et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651 -668
34. Eissele R, Brunner G, Simon B et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-717
35. Ben-Rejeb M, Bouche O, Zeitoun P. Study of 47 consecutive patients with peptic esoohageal stricture compared with 388 cases of reflux esophagitis. Dig Dis Sci 1992; 37: 733-736
36. Marks RD Richte JE, Rizzo J et al. Omeprazole vs H-2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterlogy 1994; 106: 907-915
37. Smith PM, Kerr GD, Cockel R et al. A comparison of omeprazole and ranitidine in prevention of recurrence of benign esophageal stricture. Gastroenterology 1994; 107: 1312-1318
38. Kuipers EJ, Lundell L, Klinkenberg-Knoll E et al. Atrophic gastritis and helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole for fundoplication. N Engl J Med 1996; 334: 1018-1022
39. Schenk BE, Kuipers EJ, Nelis GF et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 615-621
40. Martinek J, Blum AL, Stolte M et al. Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 27-34
41. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-16
42. Lundell L, Miettinen P, Myrvold HE et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 319-326
43. Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease. Yale J Biol Med 1999; 72: 211-218
44. Dent J. Review article: is Helicobacter pylori relevant in the management of reflux disease? Aliment Pharmacol Ther 2001; 15: 16-12
45. Hunt RH, Sumanac K, Huang JO. Review article: should we kill or should we save Helicobacter pylori? Aliment Pharmacol Ther 2001; 15: 51-59